Is a bioprosthesis preferable in tricuspid valve replacement?

Area of Science:

• Cardiac Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• Tricuspid valve disease necessitates surgical intervention, with prosthetic valve replacement being a common treatment.
• Evaluating the long-term outcomes and risks associated with different prosthetic valves is crucial for patient management.
• Understanding risk factors for mortality and morbidity post-tricuspid valve replacement is essential for improving surgical strategies.

Purpose of the Study:

• To compare the clinical outcomes of tricuspid valve replacement using Carpentier-Edwards porcine valves versus St. Jude Medical valves.
• To identify risk factors associated with mortality and morbidity following tricuspid valve replacement.
• To assess the long-term functional status and prosthetic valve performance in patients who underwent tricuspid valve replacement.

Main Methods:

• Retrospective review of clinical data from 29 patients undergoing tricuspid valve replacement between 1978 and 1995.
• Analysis of patient demographics, disease etiology (acquired vs. congenital), New York Heart Association functional class, and surgical history.
• Kaplan-Meier survival analysis to determine the probability of freedom from cardiac- and/or valve-related mortality, considering functional class and baseline disease.

Main Results:

• Hospital mortality was 17.2%, primarily in patients with acquired valvular disease and functional class IV.
• No late deaths were attributed to the tricuspid prostheses; however, nonfatal complications (thrombosis, hemolytic anemia) occurred with St. Jude valves.
• Late functional class improved to I or II in most patients, though some experienced moderate tricuspid stenosis or regurgitation with Carpentier-Edwards valves.

Conclusions:

• Both Carpentier-Edwards porcine and St. Jude Medical valves demonstrate comparable long-term outcomes in tricuspid valve replacement.
• New York Heart Association functional class IV and combined acquired valvular disease are significant risk factors for mortality.
• Patient-specific prosthesis selection is recommended to optimize outcomes in tricuspid valve replacement procedures.